Investors & Finance

Attention: open in a new window. PDFPrintE-mail

There are no translations available.

Cardio3 BioSciences raised €44.5M since inception of which €26.8M in equity. The last financing round (Series C) took place in October 2010 based on the positive data of the C-Cure Phase II trial. All proceeds are fully dedicated to development of the product pipeline...

 

Since its inception, the Company has been awarded non-dilutive financial support (grants and subsidies) from the Walloon Region and the European Commission for a total of €17.7M. The last financial support is dated January 2012. (link to the BAMI PR) . Cardio3 Biosciences intends to continue to apply for public funding to fund certain of its development and research programs. So far, all of the clinical, research and development programs are financed up to 70% by non-dilutive funding.

© 2009 Cardio 3 Biosciences

A concept of Expansion